CureVac enrols first participant in pivotal study of COVID vaccine

Germany`s CureVac announced on Monday that it has enrolled the first participant in the Phase 2b/3 study of its COVID-19 vaccine candidate.

The trial will assess the safety and efficacy in adults and is expected to include more than 35,000 participants in Europe and Latin America, it added in a statement.

(More details expected)